ZYBERNO
Stock Report
Updated Sep 1, 2026

REPLIMUNE GROUP, INC. (REPL)

Healthcare • NASDAQ

$15.50

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
REPLIMUNE GROUP, INC. (REPL) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-159.3%)
Debt-to-Equity (Solvency Risk):GOOD (0.50x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-4,033.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

REPLIMUNE GROUP, INC. (REPL) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, REPL generated -$280.00M in Owner Earnings. Capital was deployed as follows: $1.49M invested in capital expenditures. Reinvestment rate: -0.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:15.50
Market Cap:$1.50B

Valuation Multiples (2)

P/B Ratio:14.21x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.40B

Price Action & Momentum (1)

% of 52-Week High:96.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-90.8%
Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):16.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$20.32
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:29.4%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.23x
Quick Ratio:5.23x
Cash Ratio:4.83x

Leverage Analysis (3)

Debt To Equity Ttm:0.50x
Debt-to-Equity Ratio:0.50x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-40.49x
Times Interest Earned:-40.49

Capital Structure (4)

Working Capital:162,395,000.00
Cash And Cash Equivalents:185,359,000.00
Long Term Debt:$84.11M
Net Debt:-$100.11M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$297.74M

Bottom Line Performance (3)

-$297.01M
Income Before Tax:-$264.30M
Ebitda Ttm:-294,348,000.00

Operating Expenses (5)

Operating Expenses:297,744,000.00
R And D Expense:212,618,000.00
Sga Expense:85,126,000.00
Income Tax Expense:-$551.00K
Interest Expense:7,902,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$252.45M
Current Assets:$200.81M
Ppe Net:11,858,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:146,802,000.00
Current Liabilities:38,412,000.00
Long Term Debt:$84.11M
Short Term Debt:$1.14M

Equity & Capital (3)

Equity:$105.65M
Retained Earnings:-$1.33B
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,261,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:7,674,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$279.06M-$280.55M

Investment Activities (2)

Investing Cash Flow:$49.99M
Capital Expenditures Ttm:1,489,000.00

Financing Activities (3)

Financing Cash Flow:$800.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$35.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:3,396,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.15
-$3.15
Earnings Per Share Ttm:-$3.07

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.89

Book Value & Capital (2)

Book Value Per Share:$1.09
Cash Per Share:1.91

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$280.00M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):16.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-21.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:REPL
Company Name:REPLIMUNE GROUP, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:96.86M
Shares Outstanding Basic:96.86M
Shares Outstanding Diluted:96.86M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 11:42:18 UTC
Data Timestamp:2026-09-01T11:42:18.680310
Scroll to Top